Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStopping Mounjaro abruptly is not dangerous in the way that stopping some medicines can be — there is no physical withdrawal syndrome. That said, the appetite-suppressing and blood-sugar-regulating effects wear off within days to weeks, and most people regain weight if they stop without a plan in place. This is a prescription medicine, so any decision about stopping, pausing or changing your dose belongs with your prescriber, not a search engine. The right answer for you depends on your reasons for stopping, your current dose, and your health picture overall.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide has a half-life of roughly five days, meaning it takes several half-lives to clear your system fully. Most people notice appetite returning within a week of their last injection. The sensation of fullness that comes earlier in a meal, one of the more useful day-to-day effects of the medicine, fades as tirzepatide levels drop. For people who were taking Mounjaro for type 2 diabetes as well as weight management, blood-glucose control may also shift, which is a specific reason to plan any stopping with your prescriber rather than simply not ordering the next pen.
There is no documented withdrawal syndrome in the clinical sense: no shaking, no rebound blood-pressure spikes, no physiological craving driven by the medicine itself. What many people describe instead is the gradual return of their pre-treatment appetite patterns, sometimes feeling unfamiliar after months on treatment. If that experience feels distressing, it is worth raising with a clinician. The broader side-effect picture for Mounjaro is worth understanding before you start, so that what you experience on stopping does not come as a surprise.
The overall safety profile of tirzepatide is documented on the NHS tirzepatide medicine page, which also covers what to expect when treatment ends.
The honest answer is: for most people, some regain is likely if nothing else changes. The SURMOUNT programme trials showed substantial average weight reductions during treatment, but the data also show that weight tends to return after stopping, at a rate that reflects how much of the loss was driven by the medicine versus lasting behavioural changes.
That is not a reason to avoid treatment, it is a reason to use the time on treatment to build habits that persist afterwards. Protein intake, regular activity, and awareness of portion signals all matter more once tirzepatide is no longer doing part of that work. If you are considering stopping because you have hit your goal, your prescriber can help you think through a tapering or maintenance plan. The question of how long it is safe to stay on Mounjaro is closely connected to this one, and there is more detail there.
For people whose prescriber is moving them to a different treatment, the transition should be supervised. If you are weighing up whether tirzepatide is right for you in the first place, the consultation process is the right starting point.
Most people can stop Mounjaro without any acute medical event. There are, however, situations where stopping quickly or noticing specific symptoms after stopping warrants prompt attention.
If you stopped because of severe stomach pain (particularly pain that radiates toward the back, with or without vomiting) seek medical help without delay. The MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines; this can occur during treatment, but the instruction is to report severe persistent abdominal pain to a doctor urgently regardless of timing. You can also report suspected side effects, including anything you noticed before or around stopping, using the MHRA's Yellow Card scheme, this genuinely helps regulators track the real-world safety picture of medicines like tirzepatide.
Other situations worth a call to your GP or prescriber: you have type 2 diabetes and your blood-glucose readings shift significantly after stopping; you feel persistently unwell in a way you cannot explain; or you stopped abruptly at a high dose after several months on treatment and feel very different from expected. Our clinical team at nume provides aftercare seven days a week, so if you are a patient with a concern, contact is available.
For a fuller picture of GLP-1 side effects and how they are managed, the GLP-1 and tirzepatide side-effects page covers the wider landscape.
Yes, pausing is clinically possible, and for some people it is the right short-term option, for surgery, pregnancy planning, or supply reasons. Whether a pause or a stop is appropriate depends on your dose, how long you have been on treatment, and the reason for the break. A prescriber needs to be involved in that conversation.
A point worth knowing: if you pause for several weeks and then restart, your prescriber may recommend returning to a lower dose rather than picking up where you left off. GI side effects can resurface if you jump back to a higher dose after a gap. The safety considerations around Mounjaro use include this restart question, and it is covered in the product's Patient Information Leaflet.
If side effects are the reason you are thinking about stopping, that is worth raising before you make the decision. Many people find dose-related nausea or reflux improves at the current dose given time, or that a dose reduction resolves it. The page on heartburn and tirzepatide has practical detail on one of the most common stopping triggers. Our prescribers discuss suitability, side effects, and dose decisions as part of every consultation, if you are not yet a patient and want that conversation, you can start with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.